Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow which is
characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells …

Abstract Purpose of Review Immune checkpoint therapy has dramatically changed the
therapeutic landscape of solid malignancies. Here, we review the scientific rationale and …

Immunotherapy has revolutionized therapy in both solid and liquid malignancies. The ability
to cure acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an …

The last two decades of genome‐scale research revealed a complex molecular picture of
acute myeloid leukemia (AML). On the one hand, a number of mutations were discovered …

Epigenetics refers to the regulation of gene expression mainly by changes in DNA
methylation and modifications of histone proteins without altering the actual DNA sequence …

One of the fundamental hallmarks of cancer is the incapacity of the immune system to
eliminate malignancy. Cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) and lymphocyte …

The 5-year overall survival rate of AML patients remains 25–40%. The prognosis is even
more dismal for older patients who are ineligible for intensive chemotherapy and patients …

Treatment options for elderly patients with acute myeloid leukemia (AML) remain limited. In
this age group, AML is frequently associated with poor-risk features, while patients' present …

Despite recent advancements in the therapeutic landscape of acute myeloid leukemia
(AML), the prognosis of patients remains poor. Immune check point inhibitors have been …

Simple Summary Chimeric antigen receptor (CAR) T-cells are powerful therapeutic tools that
have revolutionized the treatment of several hematological malignancies. However, their …